AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
A phase 1/2 trial of AZD0120 in multiple myeloma, run by AstraZeneca, now recruiting.
Overview
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) is a phase 1/2 interventional study registered as NCT05850234 by AstraZeneca, with 232 participants planned, started 2023-07-20 and due to reach its primary completion in 2027-10-01. Interventions recorded: AZD0120.
Setting
A Phase Ib/II Study of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma (DURGA-1)
Phase
Phase 1/2
Sponsor
AstraZeneca
Registry
Enrolled
232
Similar pages
not linked directly; found by shared links- TreatmentAZD4045
Shares AstraZeneca, Multiple myeloma and the tag pipeline.
- TrialHuman BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialStudy of ODX (OsteoDex) in Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialStudy of AZD0754 in Participants With Metastatic Prostate Cancer
Shares AstraZeneca and the tag pipeline.
- TrialFirst-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer
Shares AstraZeneca and the tag pipeline.
- TrialA Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2
Shares AstraZeneca and the tag pipeline.